{"id":"W3001829806","doi":"10.1016/j.bbrc.2020.01.015","title":"The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension","year":2020,"lang":"en","type":"article","venue":"Biochemical and Biophysical Research Communications","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University; University of Toronto; Robarts Clinical Trials; St. Michael's Hospital","funders":"Novo Nordisk Canada; Canadian Institutes of Health Research; Daiichi Sankyo Company; Amgen Canada; School of Medicine; Cleveland Clinic; Forest Laboratories; Ferring Pharmaceuticals; Bristol-Myers Squibb Canada; Duke Clinical Research Institute; Eisai; Ukrainian Research Institute, Harvard University; Boston Scientific Corporation; Boehringer Ingelheim; Eli Lilly and Company; Chiesi Farmaceutici; Abbott Laboratories; CSL Behring; Precast/Prestressed Concrete Institute; AstraZeneca Canada; Accident Compensation Corporation; Mayo Clinic; Bayer; Center for Social Inclusion; Medtronic; St. Jude Medical","keywords":"Empagliflozin; Medicine; Canagliflozin; Cardiology; Internal medicine; Pulmonary hypertension; Blood pressure; Heart failure; Diabetes mellitus; Type 2 diabetes; Endocrinology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003203581,0.0001309447,0.0002138372,0.00004993524,0.0004766055,0.00005483389,0.0002914918,0.00008844695,0.000005142786],"category_scores_gemma":[0.0005412771,0.00007758378,0.00005123268,0.0004053283,0.00116816,0.00008112728,0.0009132206,0.0005937308,0.00001322554],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000442917,"about_ca_system_score_gemma":0.00008774046,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006880037,"about_ca_topic_score_gemma":0.00000179409,"domain_scores_codex":[0.9981462,0.000295846,0.000226775,0.0003611119,0.0006008379,0.000369172],"domain_scores_gemma":[0.9983066,0.0004565228,0.00002639184,0.0005402055,0.0001298168,0.0005405024],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0004208834,0.001554587,0.00406796,0.00003066926,0.00003000437,0.00009301073,0.00005208954,5.442054e-9,0.9845331,0.0001166515,0.00078042,0.008320599],"study_design_scores_gemma":[0.002504912,0.001894616,0.1754059,0.0005674565,0.00005305111,0.0001215179,0.001376983,0.008312484,0.80273,0.0007540612,0.005943828,0.0003351961],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9669217,0.008035038,1.839639e-7,0.02406528,0.000008507349,0.000631876,0.000009837069,0.00002365592,0.000303907],"genre_scores_gemma":[0.9957377,0.003500843,0.0002463305,0.0001594354,0.00007827667,0.0001539471,0.00005593641,0.00001142647,0.00005610612],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1818031,"threshold_uncertainty_score":0.4304133,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1846633630008089,"score_gpt":0.4365543621119126,"score_spread":0.2518909991111037,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}